LIPO Stock Chart & Stats
$0.03
$0.00(0.00%)
At close: 4:00 PM EDT
$0.03
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.02 - $0.64
Previous CloseN/A
Volume3.00
Average Volume (3M)7.72K
Market Cap
$151.10K
Enterprise Value-$1.34M
Total Cash (Recent Filing)$1.86M
Total Debt (Recent Filing)$264.08K
Price to Earnings (P/E)―
Beta-0.83
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding4,620,837
10 Day Avg. Volume11,317
30 Day Avg. Volume7,716
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.67
Price to Sales (P/S)5.96
P/FCF Ratio-0.81
Enterprise Value/Market Cap-8.85
Enterprise Value/Revenue-7.70
Enterprise Value/Gross Profit0.39
Enterprise Value/Ebitda0.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)-17.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsLipella announced positive results from its P2a study of LP-310 in oral lichen planus, demonstrating significant improvements across key symptoms, including reductions in pain, ulceration, and inflammation.
Regulatory ProgressFDA granted approval for an expanded access program for LP-310, its oral rinse formulation of tacrolimus, for the treatment of oral lichen planus.
Bears Say
Financial NeedsThe company will likely need to raise additional capital to fund its ongoing programs.
Lipella Pharmaceuticals, Inc. News
LIPO FAQ
What was Lipella Pharmaceuticals, Inc.’s price range in the past 12 months?
Lipella Pharmaceuticals, Inc. lowest stock price was $0.02 and its highest was $0.64 in the past 12 months.
What is Lipella Pharmaceuticals, Inc.’s market cap?
Lipella Pharmaceuticals, Inc.’s market cap is $151.10K.
When is Lipella Pharmaceuticals, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Lipella Pharmaceuticals, Inc.’s earnings last quarter?
Lipella Pharmaceuticals, Inc. released its earnings results on Mar 31, 2023. The company reported -$1.487 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.487.
Is Lipella Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Lipella Pharmaceuticals, Inc.’s price is currently Overvalued.
Does Lipella Pharmaceuticals, Inc. pay dividends?
Lipella Pharmaceuticals, Inc. does not currently pay dividends.
What is Lipella Pharmaceuticals, Inc.’s EPS estimate?
Lipella Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lipella Pharmaceuticals, Inc. have?
Lipella Pharmaceuticals, Inc. has 4,620,837 shares outstanding.
What happened to Lipella Pharmaceuticals, Inc.’s price movement after its last earnings report?
Lipella Pharmaceuticals, Inc. reported an EPS of -$1.487 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.588%.
Which hedge fund is a major shareholder of Lipella Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in LIPO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lipella Pharmaceuticals, Inc.
Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis. Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Technical Analysis
GT Biopharma
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.29% Other Institutional Investors
99.71% Public Companies and
Individual Investors